LEGEND BIOTECH ($LEGN) posted quarterly earnings results for Q4 2025 on Tuesday, March 10th. The company reported earnings of -$0.08 per share, beating estimates of -$0.11 by $0.03. The company also reported revenue of $306,300,000, missing estimates of $313,012,112 by $-6,712,112.
You can see Quiver Quantitative's $LEGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LEGEND BIOTECH Hedge Fund Activity
We have seen 97 institutional investors add shares of LEGEND BIOTECH stock to their portfolio, and 128 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 3,434,619 shares (-12.4%) from their portfolio in Q4 2025, for an estimated $74,668,617
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,969,662 shares (+100.2%) to their portfolio in Q4 2025, for an estimated $64,560,451
- SUVRETTA CAPITAL MANAGEMENT, LLC added 2,790,620 shares (+73.1%) to their portfolio in Q4 2025, for an estimated $60,668,078
- POINT72 ASSET MANAGEMENT, L.P. added 2,784,806 shares (+inf%) to their portfolio in Q4 2025, for an estimated $60,541,682
- JANUS HENDERSON GROUP PLC removed 2,125,085 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $46,199,347
- GOLDMAN SACHS GROUP INC added 1,119,049 shares (+106.0%) to their portfolio in Q4 2025, for an estimated $24,328,125
- FEDERATED HERMES, INC. removed 1,048,803 shares (-98.5%) from their portfolio in Q4 2025, for an estimated $22,800,977
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LEGEND BIOTECH Analyst Ratings
Wall Street analysts have issued reports on $LEGN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 01/20/2026
- Barclays issued a "Overweight" rating on 11/13/2025
- Cantor Fitzgerald issued a "Overweight" rating on 11/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/17/2025
To track analyst ratings and price targets for LEGEND BIOTECH, check out Quiver Quantitative's $LEGN forecast page.
LEGEND BIOTECH Price Targets
Multiple analysts have issued price targets for $LEGN recently. We have seen 9 analysts offer price targets for $LEGN in the last 6 months, with a median target of $66.0.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $80.0 on 02/04/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $50.0 on 01/22/2026
- Yaron Werber from TD Cowen set a target price of $21.0 on 01/22/2026
- Leonid Timashev from RBC Capital set a target price of $66.0 on 01/20/2026
- Trevor Allred from Oppenheimer set a target price of $75.0 on 01/07/2026
- Eric Schmidt from Cantor Fitzgerald set a target price of $74.0 on 12/17/2025
- Matthew Harrison from Morgan Stanley set a target price of $50.0 on 12/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
